Granisetron Hydrochloride

Granisetron is a potent serotonin-3 (5-HT3) receptor antagonist used to prevent nausea and vomiting caused by chemotherapy, radiation, and surgery. It works by blocking serotonin signals in the gut and brain.

Dosage for Granisetron varies significantly based on the indication and the route of administration. Healthcare providers typically follow these standard guidelines:

• Chemotherapy-Induced Nausea (Oral): The standard dose is 2 mg once daily or 1 mg twice daily. The first dose should be administered at least 1 hour before the start of chemotherapy. Subsequent doses (if prescribed for multi-day cycles) are taken 12 hours apart.
• Chemotherapy-Induced Nausea (IV): A common dose is 10 mcg/kg (micrograms per kilogram) administered intravenously over 30 seconds or diluted and infused over 5 minutes, beginning 30 minutes before chemotherapy.
• Radiation-Induced Nausea (Oral): 2 mg taken once daily, within 1 hour of the radiation treatment.
• Postoperative Nausea (IV): For prevention, 1 mg is typically administered slowly over 30 seconds before the induction of anesthesia or immediately before the end of the procedure.
• Transdermal Patch (Sancuso): One patch (3.1 mg/24 hours) is applied to the upper outer arm 24 to 48 hours before chemotherapy and can be worn for up to 7 days.

Granisetron is approved for pediatric use in specific contexts:

• CINV (IV): In children aged 2 to 16 years, the recommended dose is 10 mcg/kg, administered 30 minutes before chemotherapy.
• CINV (Oral): Safety and effectiveness of oral Granisetron in pediatric patients have not been as extensively established as the IV route, though some clinicians use weight-based oral dosing off-label. Always consult a pediatric oncologist for specific instructions.
• PONV: Granisetron is not widely recommended for the prevention of postoperative nausea in children due to limited clinical trial data compared to other agents like ondansetron.

Renal Impairment

In patients with renal failure or significant kidney impairment, studies suggest that dosage adjustments are generally not required. The pharmacokinetics of Granisetron are not substantially altered by decreased kidney function, although patients should be monitored for any increase in side effects.

Hepatic Impairment

For patients with hepatic (liver) impairment, the clearance of Granisetron may be reduced, leading to a longer half-life. While the FDA-approved labeling does not mandate specific dose reductions for mild to moderate liver disease, healthcare providers should exercise caution in patients with severe hepatic impairment (e.g., advanced cirrhosis).

Elderly Patients

No specific dosage adjustments are required for geriatric patients (aged 65 and older). However, because older adults are more likely to have decreased renal or hepatic function and are often on multiple medications, clinicians typically start at the lower end of the dosing range.

• Oral Tablets: Swallow the tablet whole with a full glass of water. It can be taken with or without food. If you are taking it to prevent chemotherapy nausea, timing is critical—ensure you take it at least 60 minutes before your session begins.
• Transdermal Patch: Apply the patch to clean, dry, hairless skin on the upper outer arm. Do not apply to skin that is red, irritated, or cut. Avoid exposing the patch site to direct sunlight or heat lamps, as heat can increase the rate of drug absorption.
• Storage: Store oral forms at room temperature (68°F to 77°F) away from moisture and light. Keep all medications out of the reach of children.

If you miss a dose of Granisetron, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular schedule. Do not 'double up' or take two doses at once. Because this medication is often used on a strict schedule before medical treatments, missing a dose may result in breakthrough nausea.

There is no specific antidote for Granisetron overdose. Signs of overdose may include extreme headache, dizziness, or a 'pounding' heartbeat. In the event of a suspected overdose, contact your local poison control center or seek emergency medical attention immediately. Treatment is generally supportive, focusing on managing symptoms and maintaining vital functions.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or stop taking the medication without medical guidance, especially if you are undergoing a multi-day chemotherapy regimen.

Granisetron is generally well-tolerated, but like all medications, it can cause side effects. The most frequently reported adverse reactions include:

• Headache: This is the most common side effect, occurring in up to 15-20% of patients. It is thought to be caused by the drug's effect on serotonin receptors in the cranial blood vessels. These headaches are usually mild to moderate and can often be managed with over-the-counter pain relievers (after consulting your doctor).
• Constipation: Serotonin plays a vital role in gut motility (the movement of the intestines). By blocking serotonin receptors in the gut, Granisetron can slow down digestion, leading to constipation. This effect is usually temporary but may require increased fluid intake or stool softeners.
• Asthenia (Weakness/Tiredness): Some patients report a general feeling of fatigue or lack of energy following administration, though this can be difficult to distinguish from the effects of chemotherapy itself.

Granisetron is a potent medication that must be used with caution in patients with certain underlying health conditions. Before starting treatment, ensure your healthcare provider is aware of your full medical history, particularly any history of heart rhythm disorders or electrolyte imbalances. While Granisetron does not typically cause sedation, it can cause dizziness in some patients, which may impair the ability to perform tasks requiring alertness.

No FDA black box warnings for Granisetron. It is considered to have a favorable safety profile compared to many other medications used in the oncology setting.

• QT Prolongation: Granisetron has been associated with changes in the EKG (electrocardiogram), specifically the prolongation of the QT interval. This can lead to a dangerous heart rhythm known as Torsade de Pointes. This risk is significantly increased in patients with 'Long QT Syndrome,' congestive heart failure, or those taking other medications that affect heart rhythm.

• Apomorphine: The use of Granisetron with apomorphine (a drug used for Parkinson's disease) is generally contraindicated. Combining these drugs can lead to a profound drop in blood pressure (hypotension) and loss of consciousness. This interaction has been documented with other 5-HT3 antagonists and is assumed to be a class effect.

• Serotonergic Drugs: This includes SSRIs (like fluoxetine/Prozac), SNRIs (like venlafaxine/Effexor), MAOIs, and tricyclic antidepressants. The combination increases the risk of Serotonin Syndrome, a life-threatening condition. Symptoms include high fever, muscle rigidity, and mental status changes.
• QT-Prolonging Agents: Drugs such as amiodarone, sotalol, certain antipsychotics (like haloperidol), and certain antibiotics (like erythromycin or clarithromycin) can increase the risk of dangerous heart rhythms when taken with Granisetron.

Granisetron must NEVER be used in the following situations:

• Known Hypersensitivity: If you have had a documented severe allergic reaction (anaphylaxis, angioedema, or severe rash) to Granisetron or any component of the formulation (such as the adhesive in the Sancuso patch), you must not use this drug.
• Concomitant Apomorphine Use: Due to the risk of severe hypotension and loss of consciousness, the simultaneous use of Granisetron and apomorphine is strictly prohibited.

These are conditions where the drug should be used only if the benefits clearly outweigh the risks, and under close medical supervision:

• Congenital Long QT Syndrome: Patients born with this heart rhythm abnormality are at a much higher risk for fatal arrhythmias if they take Granisetron.

Granisetron is generally classified as Pregnancy Category B (or equivalent in modern labeling), meaning that animal studies have failed to demonstrate a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women.

• First Trimester: Most clinicians recommend avoiding Granisetron during the first trimester unless the nausea (such as hyperemesis gravidarum) is life-threatening and other treatments have failed.
• Risks: While not considered a known teratogen (substance that causes birth defects), the data is much more limited for Granisetron than for ondansetron.
• Decision Making: Use during pregnancy should be based on a careful risk-benefit analysis by an obstetrician and the patient.

It is not known whether Granisetron is excreted in human milk. However, because many drugs are excreted in breast milk, caution should be exercised. Animal studies have shown the presence of the drug in the milk of lactating rats. If Granisetron is necessary for the mother, a decision should be made whether to discontinue nursing for 24 hours after the dose or to use an alternative antiemetic with a better-established safety profile in breastfeeding.

Granisetron is a potent and highly selective antagonist of 5-hydroxytryptamine (5-HT3) receptors. These receptors are ligand-gated ion channels located peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone (CTZ) of the area postrema. During chemotherapy or radiation, mucosal damage in the small intestine causes the release of serotonin from enterochromaffin cells. This serotonin stimulates the 5-HT3 receptors on the vagus nerve, initiating the vomiting reflex. Granisetron binds to these receptors with high affinity, preventing their activation by serotonin. This blockade interrupts the signaling pathway that would otherwise lead to the sensation of nausea and the physical act of vomiting.

Granisetron's effects are dose-dependent up to a certain point, after which a plateau is reached. It does not affect lower esophageal sphincter pressure, gastrointestinal transit time (in a way that causes acute distress, though it does cause constipation), or gastric emptying. It has no significant affinity for other serotonin receptor subtypes or for alpha- or beta-adrenoceptors, dopamine D2 receptors, or histamine H1 receptors. This selectivity is why it does not cause the sedation or movement disorders associated with older antiemetic classes.